SCHEMBL21189211

SCHEMBL21189211

CC(C)(CCCC(C)(C)C(C)(C)CCOC(C)(C)C)NS(C)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17520404 0.71 DUT (0.36)
SCHEMBL4790668 0.71 CA1 (0.34)
SCHEMBL17520385 0.70 DUT (0.35)
SCHEMBL17520383 0.68 EPHX1 (0.37)
SCHEMBL24522266 0.66 TRPA1 (0.32)
SCHEMBL13164464 0.66 ALDH1A1 (0.39)
SCHEMBL19798739 0.64 POLB (0.39)
SCHEMBL18859420 0.63 ALDH1A1 (0.38)
SCHEMBL9965243 0.62 USP2 (0.32)
SCHEMBL13126748 0.62 L3MBTL1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919877-B2 Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-02-16 US disclosed
US-20190224207-A1 MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-07-25 US disclosed